Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced the approval of its phase 1b/2 clinical trial application for HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07 for treating advanced/metastatic solid tumors. This approval by the National Medical Products Administration marks a significant step in the company’s clinical development efforts, potentially enhancing its market position in oncology therapeutics. The trial’s previous data demonstrated promising results, showing high response rates and good safety profiles, especially in patients with advanced non-small cell lung cancer, indicating a positive outlook for stakeholders.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of innovative biologic drugs. The company specializes in antibody-drug conjugates and monoclonal antibodies, targeting various advanced and metastatic solid tumors.
Average Trading Volume: 1,446,389
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.89B
See more data about 2696 stock on TipRanks’ Stock Analysis page.